IR@PKUHSC  > 基础医学院  > 细胞生物学系
学科主题基础医学
Spotlight on decitabine for myelodysplastic syndromes in Chinese patients
Jing, Yu1; Shen, Xue2; Mei, Qian3; Han, Weidong3
关键词Myelodysplastic Syndromes (Mdss) Decitabine Hypomethylating Agents People&Prime s Republic Of China Traditional Chinese Medicine
刊名ONCOTARGETS AND THERAPY
2015
DOI10.2147/OTT.S81093
8
收录类别SCI
文章类型Review
WOS标题词Science & Technology
类目[WOS]Biotechnology & Applied Microbiology ; Oncology
资助者National Natural Science Foundation of China ; Beijing Nova Program ; National Natural Science Foundation of China ; Beijing Nova Program
研究领域[WOS]Biotechnology & Applied Microbiology ; Oncology
关键词[WOS]ACUTE MYELOID-LEUKEMIA ; CONVENTIONAL CARE REGIMENS ; EPIGENETIC THERAPY ; PHASE-III ; 5-AZA-2&prime ; -DEOXYCYTIDINE DECITABINE ; ELDERLY-PATIENTS ; CANCER-PATIENTS ; SOLID TUMORS ; AZACITIDINE ; MULTICENTER
英文摘要

Myelodysplastic syndromes (MDSs) are a group of heterogeneous clonal hematopoietic stem cell malignancies with advanced median age. The silencing of tumor suppressor genes caused by DNA hypermethylation plays a crucial role in the pathogenesis of MDS. Decitabine, the available hypomethylating agent, is successfully used for the treatment and improves the outcome of MDS, and has become one of the most frequently administered disease-modifying therapies. With an aging population and a growing number of people exposed to benzene, the incidence of MDS has been increasing rapidly. The blinded regimen choice and the lack of a unified strategy create challenges for the treatment of MDS. Here, we present a review of clinical progress and prospects of decitabine treatment of MDS in the People′s Republic of China. We also discuss the optimization of therapy issues to improve the cure rate and prolong survival in patients with MDS.

语种英语
所属项目编号81230061 ; 31270820 ; 81272867 ; Z131107000413103
资助者National Natural Science Foundation of China ; Beijing Nova Program ; National Natural Science Foundation of China ; Beijing Nova Program
WOS记录号WOS:000362294600001
引用统计
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/58112
专题基础医学院_细胞生物学系
作者单位1.Peoples Liberat Army Gen Hosp, Dept Hematol, Beijing, Peoples R China
2.Peking Univ, Hlth Sci Ctr, Sch Basic Med Sci, Dept Cell Biol, Beijing 100871, Peoples R China
3.Chinese Peoples Liberat Army Gen Hosp, Inst Basic Med, Dept Mol Biol, Beijing 100853, Peoples R China
推荐引用方式
GB/T 7714
Jing, Yu,Shen, Xue,Mei, Qian,et al. Spotlight on decitabine for myelodysplastic syndromes in Chinese patients[J]. ONCOTARGETS AND THERAPY,2015,8.
APA Jing, Yu,Shen, Xue,Mei, Qian,&Han, Weidong.(2015).Spotlight on decitabine for myelodysplastic syndromes in Chinese patients.ONCOTARGETS AND THERAPY,8.
MLA Jing, Yu,et al."Spotlight on decitabine for myelodysplastic syndromes in Chinese patients".ONCOTARGETS AND THERAPY 8(2015).
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Jing, Yu]的文章
[Shen, Xue]的文章
[Mei, Qian]的文章
百度学术
百度学术中相似的文章
[Jing, Yu]的文章
[Shen, Xue]的文章
[Mei, Qian]的文章
必应学术
必应学术中相似的文章
[Jing, Yu]的文章
[Shen, Xue]的文章
[Mei, Qian]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。